NCT04305756 is a NA clinical trial of Enoxaparin in Thromboembolism, sponsored by University of Utah.

Who is sponsoring NCT04305756?

NCT04305756 is sponsored by University of Utah.

What drugs are being tested in NCT04305756?

Interventions in NCT04305756: Enoxaparin.

What condition does NCT04305756 study?

NCT04305756 studies Thromboembolism, Postpartum DVT, Thrombosis.

Is NCT04305756 still recruiting?

NCT04305756 is currently completed. Last updated 28 January 2022.

Last reviewed 2022-01-28 · How we verify

NCT04305756

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery

Completed NA Last updated 28 January 2022

What this trial tests

NA trial testing Enoxaparin in Thromboembolism in 146 participants. Completed in 15 December 2021.

Timeline

12 June 2020

Primary endpoint
15 December 2021

15 December 2021

Quick facts

Lead sponsor	University of Utah
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	146
Start date	12 June 2020
Primary completion	15 December 2021
Estimated completion	15 December 2021
Sites	1 location across United States

Drugs / interventions tested

Enoxaparin — full drug profile →

Conditions studied

Thromboembolism — all drugs for Thromboembolism →
Postpartum DVT — all drugs for Postpartum DVT →
Thrombosis — all drugs for Thrombosis →

Sponsor

University of Utah

Who can join

Adults 18 to 55, female only, with Thromboembolism or Postpartum DVT. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the efficacy of two dosing regimens of low molecular weight heparin (LMWH) to reach prophylactic anti-factor Xa levels in post-cesarean delivery women. Half of participants will receive a fixed dose of LMWH, while the other half will receive a weight-based dose. The hypothesis is that the use of a weight-based dose will result in more women reaching prophylactic levels.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period.
Middleton P, Shepherd E, Gomersall JC. · · 2021 · cited 43× · PMID 33779986 · DOI 10.1002/14651858.cd001689.pub4
Weight-Based Compared With Fixed-Dose Enoxaparin Prophylaxis After Cesarean Delivery: A Randomized Controlled Trial.
Bruno AM, Allshouse AA, Campbell HM, Branch DW, et al · · 2022 · cited 14× · PMID 36075079 · DOI 10.1097/aog.0000000000004937

Verify or expand the search:

Other trials of Enoxaparin

Trials testing the same drug.

NCT07462182 — Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction · NA · not yet recruiting
NCT07312851 — A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Parti · Phase 1 · recruiting
NCT07015905 — REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults · Phase 3 · recruiting
NCT06818279 — Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis · Phase 2, PHASE3 · not yet recruiting
NCT06689241 — Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery · NA · recruiting

Other recruiting trials for Thromboembolism

Currently open trials in the same condition.

NCT06657924 — Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery · Phase 2 · recruiting
NCT06442267 — Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support · Phase 4 · recruiting
NCT06443905 — Xueshuantong Injection (Lyophilized) in the Prevention of Venous Thromboembolism (VTE) in Hospitalized Patients · active not recruiting
NCT05301348 — In Vivo Detection of Circulating Clots in Patients With Thromboembolism · NA · recruiting
NCT06627933 — Optimization of Management in Patients With Cardiovascular Disease After Lower Limb Joint Replacement · recruiting

Other University of Utah trials

Trials by the same sponsor.

NCT07515755 — Supplemental Oxygen and Oxygen Desaturations in Colonoscopies · NA · not yet recruiting
NCT07225426 — Personalizing Financial Incentives · NA · recruiting
NCT06716411 — Confirming the Effects of Acupuncture Treatments to Relieve Symptoms of Gulf War Illness · NA · recruiting
NCT07246538 — Positive Airway Pressure (PAP) System Evaluation in Volunteers · NA · not yet recruiting
NCT04208984 — Diversion Device With Breath Control · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04305756 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Utah
Last refreshed: 28 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04305756.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing